SRI is conducting preclinical development of treatments for diseases such as tuberculosis, West Nile virus, hepatitis, and biodefense pathogens and toxins.
SRI is identifying candidates for advanced therapies in multiple disease areas by developing compounds from synthetically optimized, natural dietary products.
SRI is seeking new treatments for tuberculosis, a global health crisis.
SRI is developing a new therapeutic agent for influenza virus infections.
SRI is elucidating the mechanism of action of the drug of choice for the treatment of all known forms of human schistosomiasis.
Partnering to Rapidly Advance ZMapp® for Ebola Treatment
To help prepare for next-generation pandemics, SRI is partnering with Stanford University to examine vaccination responses.